Performance test and analysis of tetracycline degradation using a Micro-Nano Bubble system.

Antibiotics and organic residues from Tetracycline (TC) and other pharmaceuticals administered to aquatic living organism have negative impacts on aquatic environment by killing-off non-target living organisms and developing antibiotic-resistant bacteria. In this study, Micro-Nano Bubble (MNB) system was used to remove TC residues. MNB system demonstrated good level of degradation efficiency, as resulted in experiment where in time of 100 min, the TC degraded at rate of 82.66% from its initial concentration of TC when the initial concentration was 1 mg/L. When the initial concentration was increased to 10 mg/L, MNB system degraded TC at 64.35% of their initial, this means MNB system demonstrated good level of efficiency for TC removal and indicated that it is more efficient in TC degradation under the conditions of low initial TC concentration and high availability of dissolved oxygen (DO). In the system as the temperature increased there was a significant decrease in DO saturation which was related to the TC complex structure that contain multiple function groups such as amino groups, hydroxyl and carboxyl which possess high strong affinity with oxygen that leads to their adsorption onto bubble surface. This study provides significant insights into the application of MNB system for the removal of organic residues within aquatic ecosystem and underscores the need for further exploration of MNB technology for environmental remediation.

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD-1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.